Table 3.
The laboratory findings in psoriasis, PsA and RA groups.
| mean ± sd (min-max; median) | Psoriasis (n= 50) | PsA (n= 55) | RA (n= 50) | p |
|---|---|---|---|---|
| Fasting Glucose (mg/dL) | 96.1 ± 1.4 (76–142; 92) | 98.1 ± 2.2 (65–191; 94) | 95.0 ± 1.6 (64–122; 91.5) | 0.865 |
| HbA1c (%) | 5.8 ± 0.5 (5–7; 5.7) | 5.9 ± 0.6 (5–7.5; 5.7) | 5.7 ± 0.6 (4.1–7.1; 5.7) | 0.235 |
| Total Cholesterol (mg/dL) | 195.4 ± 46.2 (102–311; 189.5) | 209.0 ± 42.2 (74–350; 211) | 199.4 ± 39.7 (109–282; 196) | 0.217 |
| LDL (mg/dL) | 124.7 ± 37.1 (58.2–221; 121.9) | 129.5 ± 35.4 (37.4–275; 121) | 122.7 ± 32.3 (65–179; 116.8) | 0.508 |
| VLDL (mg/dL) | 27.9 ± 1.5 (8.8–69.6; 25.6) | 28.0 ± 1.8 (8.8–103; 23.6) | 21.7 ± 1.0 (8.6–51.4; 19.6) | 0.067 |
| HDL (mg/dL) | 42.6 ± 1.0 (21–66; 42) | 51.0 ± 1.1 (24–84; 50) | 55.3 ± 1.3 (21–87; 52.5) | 0.000* |
| Triglycerides (mg/dL) | 138.7 ± 74.0 (44–348; 126) | 142.2 ± 87.0 (44–515; 122) | 109.3 ± 51.6 (43–257; 98) | 0.063 |
| Insulin (μünite/mL) | 15.3 ± 1.1 (1.7–57.2; 12.3) | 16.2 ± 1.1 (4.5–49.2; 12.9) | 16.5 ± 1.2 (4.3–56.9; 12.2) | 0.917 |
| C-peptide (pmol/mL) | 2,.9 ± 2.0 (1.2–11.1; 2.2) | 2.8 ± 2.3 (1.1–17.3; 2.2) | 3.0 ± 1.7 (1.0–9.7; 2.7) | 0.306 |
| HOMA | 3.7 ± 2.6 (1.3–13.0; 2.8) | 4.0 ± 3.2 (0.9–13.6; 2.8) | 4.3 ± 3.7 (0.9–16; 3.0) | 0.902 |
| BMI (kg/m2) | 27.0 ± 4.9 (19–40; 26.5) | 28.8 ± 4.4 (18–38; 29) | 27.9 ± 6.0 (15–47; 28) | 0.115 |
| CRP (mg/dL) | 1.0 ± 1.9 (0.1–12.2; 0.5) | 0.7 ± 1.3 (0.02–6.5; 0.3) | 1.5 ± 3.7 (0.03–26.2; 0.7) | 0.013* |
| ESR (mm/h) | 16.2 ± 1.2 (2–66; 13) | 18.6 ± 1.7 (2–74; 14) | 24.6 ± 2.0 (2–91; 18.5) | 0.089 |
n: number; PsA: psoriatic arthritis; RA: rheumatoid arthritis; F: female; M: male; HbA1c: hemoglobin A1c; LDL: low density lipoprotein; HDL: high density lipoprotein; VLDL: very low density lipoprotein; HOMA: homeostasis model assessment; BMI: body mass index, CRP: c-reactive protein; ESR: eritrocyte sedimentation rate.
*
p<0.05 is statistically significant.